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Objective: Targeted drugs dramatically improve the treatment outcomes in cancer patients; however,
these innovative drugs are often associated with unexpectedly high cardiovascular toxicity. Currently,
cardiovascular safety represents both a challenging issue for drug developers, regulators, researchers,
and clinicians and a concern for patients. While FDA drug labels have captured many of these events,
spontaneous reporting systems are a main source for post-marketing drug safety surveillance in ‘real-
world’ (outside of clinical trials) cancer patients. In this study, we present approaches to extracting, pri-
oritizing, ﬁltering, and conﬁrming cardiovascular events associated with targeted cancer drugs from the
FDA Adverse Event Reporting System (FAERS).
Data and methods: The dataset includes records of 4,285,097 patients from FAERS. We ﬁrst extracted
drug–cardiovascular event (drug–CV) pairs from FAERS through named entity recognition and mapping
processes. We then compared six ranking algorithms in prioritizing true positive signals among extracted
pairs using known drug–CV pairs derived from FDA drug labels. We also developed three ﬁltering algo-
rithms to further improve precision. Finally, we manually validated extracted drug–CV pairs using 21
million published MEDLINE records.
Results: We extracted a total of 11,173 drug–CV pairs from FAERS. We showed that ranking by frequency
is signiﬁcantly more effective than by the ﬁve standard signal detection methods (246% improvement in
precision for top-ranked pairs). The ﬁltering algorithm we developed further improved overall precision
by 91.3%. By manual curation using literature evidence, we show that about 51.9% of the 617 drug–CV
pairs that appeared in both FAERS and MEDLINE sentences are true positives. In addition, 80.6% of these
positive pairs have not been captured by FDA drug labeling.
Conclusions: The unique drug–CV association dataset that we created based on FAERS could facilitate our
understanding and prediction of cardiotoxic events associated with targeted cancer drugs.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Treatment outcomes in cancer patients have dramatically im-
proved since the introduction of targeted drugs. However, targeted
drugs are often associated with unexpectedly high cardiovascular
toxicity in cancer patients [1,2]. The mechanisms by which tar-
geted drugs become cardiotoxic in cancer patients are not well-
understood [3–5]. To ensure personalized cancer treatment, re-
search efforts are needed to understand cardiovascular toxicitiesassociated with targeted drugs. Toxic effects on the heart and vas-
cular system caused by targeted cancer drugs can reveal insights
into the biology of cardiovascular disease in humans [6]. System-
atic and integrated approaches to studying cardiovascular events
associated with targeted drugs have high potential for elucidating
the complex pathways of drug-induced toxicities, identifying the
on- and off-targets of undesirable cardiovascular events, and pre-
dicting unknown cardiotoxicities [7–9]. However, systematic study
of targeted drug-induced cardiovascular events has been ham-
pered by the lack of a comprehensive and machine-understandable
knowledge base of drug-associated cardiotoxicity in cancer
patients. This knowledge is often buried throughout multiple
disparate and complementary information sources in various
formats, including the U.S. Food and Drug Administration (FDA)
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ature (commercial drugs, drugs under preclinical or clinical devel-
opment, and even failed drugs), the FDA Adverse Event Reporting
System (FAERS) (commercial drugs), and patient electronic health
records (EHRs) (commercial drugs). Our long-term research goal
is to extract drug–side effect (drug–SE) relationships for cancer
drugs from all these information sources and build a comprehen-
sive cancer toxicity knowledge base. In this study, we focus on
mining cardiovascular events associated with targeted cancer
drugs (drug–CV) from the FDA post-marketing FAERS database,
which holds data on more than 4.2 million patients, including
443,226 cancer patients. The unique dataset of drug–CV relation-
ship we have created could facilitate our understanding of the
underlying biological mechanisms of the toxic effects under con-
sideration, the development of computational models predictive
of adverse events related to targeted cancer therapies, the identiﬁ-
cation of cancer patients at risk for speciﬁc cardiovascular toxic
events, and understanding the biology of cardiovascular disease
in humans. Ultimately, our database can potentially capacitate
the achievement of more effective, safer, and more personalized
cancer care. As far as we know, this is the ﬁrst study to systemat-
ically extract, rank, ﬁlter, and conﬁrm cardiovascular events asso-
ciated with targeted anticancer drugs using large amount of
published biomedical literature.
Targeted cancer drugs control cancer cell proliferation and
spread by interfering with speciﬁc molecular targets involved in
tumor growth and progression [13]. Targeted cancer therapies
have signiﬁcantly (positively) impacted the survival and quality
of life of cancer patients [2]. Currently, approximately 500 novel
targeted anti-cancer agents are under preclinical or clinical devel-
opment or have been approved by the FDA for the treatment of
speciﬁc types of cancers [13,14]. Targeted cancer drugs promise
new ways to personalize cancer treatments based on the unique
molecular targets expressed by tumor cells. However, a major chal-
lenge posed by these targeted agents lies in maintaining the bal-
ance between tumor control and drug-induced toxicity [2],
especially cardiotoxicity, which represents one of the most signif-
icant complications of targeted drug use in cancer patients [15].
The mechanisms by which targeted agents manifest their cardio-
toxicity remain unclear [3–5]. Unlike the side effects induced by
non-speciﬁc cytotoxic chemotherapeutics, which are often similar,
cardiotoxicity associated with targeted cancer drugs often differ
among even drugs of the same class such as erlotinib and geﬁtinib
[16]. Currently available approaches in predicting the cardiotoxic-
ity of targeted drugs have had limited success [17], demonstrating
the need for researchers to gain mechanistic insight into cardiotox-
icity associated with targeted drug use in cancer patients.
Side effects, including drug-induced cardiotoxicity, are observa-
ble phenotypes of drugs at the level of the whole body system and
are mediated by a drug interacting with its targets through a cas-
cade of downstream pathway perturbations [18]. Systems biology
creates the capability to elucidate complex and highly intercon-
nected pathways of toxicities and to develop computational mod-
els predictive of unknown toxicities [8–10]. It has been
increasingly recognized that similar side effects of seemingly unre-
lated drugs can be caused by their common off-targets and that
drugs with similar side effects are likely to share molecular targets
[19]. Therefore, systems approaches to studying the phenotypic
relationships among targeted cancer drugs and integration of this
drug phenotypic data with genetic and other ‘omics’ data, such
as protein–target interactions, chemical structure, and gene
co-expression, will allow for a better understanding of drug toxic-
ities. For phenotype-driven systems approaches to understanding
targeted drug-induced cardiotoxicity in cancer patients, the
availability of a comprehensive and machine-understandable
drug–cardiovascular events (drug–CV) relationship knowledgebase is critical. At present, no such data source exists and the pub-
lished literature on automatically extracting drug–SE relationships
for cancer drugs is scant.
It was recently demonstrated that 39% of serious events associ-
ated with targeted cancer drugs are not reported in clinical trials
and 49% are not described in FDA drug labels [20]. In addition,
the accelerated approval of anticancer drugs initiated by the FDA
in 1992may cause the early release of unsafe drugs [21]. Therefore,
to build a comprehensive knowledge base of drug–SE relationships
for cancer drugs, it is important to extract knowledge from multi-
ple sources, including FDA drug labels, the FDA post-market drug
safety surveillance system FAERS, patient EHRs, and the large body
of published biomedical literature. Recently, we developed a
simple but effective method for extracting a large number of
drug–SE pairs for cancer drugs from published biomedical litera-
ture abstracts [11]. In this study, we focus on mining targeted
cancer drug-related cardiovascular events from FAERS, which
includes data for more than 4.4 million patients.
Spontaneous reporting systems are the main resources for post-
marketing drug safety surveillance. Mining drug–SE relationships
from FAERS is a highly active area. Data mining algorithms such
as disproportionality analysis, correlation analysis, and multivari-
ate regression have been developed to detect adverse drug signals
from FAERS [22–26]. Current signal detection methods often suffer
from a range of limitations including biased reporting and misattri-
bution of causality in drug–SE combinations [27]. Therefore, it is
important to develop robust signal detection methods to identify
anticancer drug-related adverse events from FAERS. In this study,
we developed a simple signal-ranking method that is more effec-
tive than standard signal detection approaches. We also developed
three signal-ﬁltering methods to further improve precisions. After
these initial signal detection and strengthening steps, we con-
ﬁrmed extracted CV pairs by manually looking for evidence in
the 21 million published MEDLINE records.2. Data and methods
The processing of detecting cardiovascular events associated
with targeted cancer drugs is depicted in Fig. 1 and consisted of
the following steps: (1) Extracting drug–CV pairs from FAERS
through named entity recognition and drug mapping processes;
(2) ranking extracted drug–CV pairs by comparing six different
ranking approaches; (3) ﬁltering extracted drug–CV pairs by
removing false positives (drug–disease treatment pairs and dis-
ease–manifestation pairs) and by extracting drug–CV pairs from
patients taking single drug; and (4) manual curation of all ex-
tracted drug–CV pairs that appeared in MEDLINE sentences.2.1. Data
2.1.1. FDA Adverse Event Reporting System (FAERS)
The FDA FAERS data ﬁles for the time period from year 2004
through 2012 were downloaded [12]. A total of 4,285,097 records
were extracted from the downloaded datasets. Among the down-
loaded ﬁles, ﬁles DRUGyyQq.TXT contain drug information associ-
ated with reported adverse event. Files REACyyQq.TXT contain all
‘‘Medical Dictionary for Regulatory Activities’’ (MedDRA) terms
coded for an adverse event. Files DRUGyyQq.TXT and REAC-
yyQq.TXT are the sources of drug–CV association extraction. Files
INDIyyQq.TXT contain patients’ disease information, which was
used in our study to stratify patients into cancer and non-cancer
populations. Files DEMOyyQq.TXT contain patients’ demographic
information, such as age and gender, which was used in our study
to stratify patients into different demographic groups.
Fig. 1. Experimental ﬂow chart.
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A list of 45 targeted cancer drugs (including both generic names
and trade names) that are FDA-approved or being studied in ongo-
ing clinical trials was obtained from the National Cancer Institute
(NCI) [13].
2.1.3. Lexicon of cardiovascular event (CV) terms
We built a lexicon of CV terms based on MedDRA, which is a
widely-used medical terminology to classify adverse event infor-
mation associated with the use of biopharmaceuticals and other
medical products [29]. The adverse events in FAERS are also coded
with MedDRA terms. The lexicon was created by ﬁnding all leaf
nodes with the ancestor ‘‘vascular disorders’’ or ‘‘cardiac disor-
ders.’’ This lexicon consisted of a total of 1712 CV terms, including
1269 vascular disorders and 527 cardiac disorders.
2.2. Methods
2.2.1. Extraction of drug–CV pairs from FAERS
The drug–CV pairs were extracted by linking DRUGyyQq.TXT
with REACyyQq.TXT using patient report ID numbers. We then
cleaned up the extracted pairs as following: (1) drug entity recog-
nition and mapping: drug names used in DRUGyyQq.TXT often
consisted of drug trade name, generic name, or both. In addition,
many drug strings are in free text form. We performed drug entity
recognition and mapped trade names to generic names. We ﬁrst
built a drug lexicon consisting of both generic names (i.e. Trast-
uzumab) and trade names (i.e. Herceptin) for the 45 targeted
drugs. The trade names We then recognized drug entities (both
trade names and generic names) from drug strings through a sim-
ple dictionary-based exact string match process. After named en-
tity recognition, we then mapped all trade names to their
corresponding generic names. For example, from the drug string
‘‘herceptin (trastuzumab) pwdr + solvent, infusion soln, 440mg’’,
we ﬁrst recognized the two drug terms ‘‘Herceptin’’ and ‘‘trast-
uzumab’’ using the drug lexicon that consisted of both drug generic
names and trade names. We then mapped the trade name ‘‘Her-
ceptin’’ to its generic name ‘‘trastuzumab.’’ Therefore, from the
above free-text drug string, we extracted one drug entity ‘‘trast-
uzumab.’’ (2) CV entity recognition: CV entities were recognized
from adverse event strings in the REACYYQq.TXT ﬁles using a dic-
tionary-based exact string matching approach. The dictionary of
CV terms was created as above and consisted of a total of 1712
CV terms, including 1269 vascular disorders and 527 cardiac
disorders.
After these two steps, we obtained a total of 11,173 drug–CV
pairs, representing 39 (out of 45) targeted drugs and 1097 (out of
1712) CV events. Six targeted drugs (bosutinib, cabozantinib, car-
ﬁlzomib, crizotinib, regorafenib, and ziv-aﬂibercept) were not in
the database since the list of targeted cancer drugs included both
FDA-approved drugs and drugs still in ongoing clinical trials. These
six drugs are presumably still in clinical trial stages.2.2.2. Prioritizing extracted drug–CV pairs
We ranked the extracted drug–CV pairs using six measures: fre-
quency, relative reporting ration (RRR), proportional reporting ra-
tio (PRR), reporting odds ratio (ROR), phi coefﬁcient (PhiCorr),
and information component (IC). Frequency is the co-occurrence
count of a drug–CV pair in the database. The RRR, PRR, ROR, Phi-
Corr, and IC are popular signal detection methods based on fre-
quency analysis of 2  2 contingency tables to estimate statistical
association of a drug-adverse event pair in the databases [22–27].
In order to compare different ranking methods, we used 11-
point interpolated average precision, which is commonly used to
evaluate retrieved ranked lists for search engines [30]. For each
ranked list, the interpolated precision was measured at the 11 re-
call levels of 0.0,0.1,0.2, . . .,1.0. At each recall level, we calculated
the arithmetic mean of the interpolated precision. A composite
precision–recall curve showing 11 points was then graphed.
It is often difﬁcult to evaluate the performance of signal detec-
tion from FAERS since we do not have a gold standard that accu-
rately represents the space of all true positive signals (including
both known true positives and unknown true positives) reported
in FAERS. In order to compare these six ranking approaches in pri-
oritizing true signals, we used a total of 259 drug–CV pairs ex-
tracted from FDA drug labels as the evaluation dataset. These
pairs contain not only true signals reported in pre-marketing con-
trolled clinical trials (major portion) but also many conﬁrmed post-
marketing signals. Note this evaluation dataset was not intended
to calculate the true precisions and recalls, but to compare the
six ranking approaches in prioritizing true signals. The advantages
in this evaluation dataset are that it is mainly comprised true pos-
itives and it is not biased towards speciﬁc drugs or CV events. The
limitation is that we cannot measure the true precision and recall
of drug–CV pair extraction from FAERS.
For creating the gold standard, we downloaded a total of 44,979
drug labels, including 21,610 Human prescription labels, and
23,369 Human OTC labels, from DailyMed [31]. DailyMed is main-
tained by the National Library of Medicine (NLM) and provides
high quality information about marketed drugs. Drug labeling on
DailyMed is the most recent FDA labels (package inserts). Majority
of the drug side effect information on FDA drug labels was obtained
from clinical trials and some was from post-marketing surveil-
lance. We used the publically available information retrieval li-
brary Lucene (http://lucene.apache.org) to create a local FDA
drug label search engine with indices created on both drugs, sec-
tion headers in the labels such as ‘‘Indications,’’ ‘‘Contraindica-
tions,’’ and ‘‘Adverse Reactions’’ and sentences. Each sentence
was associated with a drug and a subsection header name. We
used each of the 45 * 1712 drug–CV combinations (45 targeted
drugs and 1712 CV terms) as search queries to the local FDA drug
label search engine. Drug–CV pairs that appeared in sentences with
header ‘‘Adverse Reactions’’ were retrieved. We extracted a total of
259 drug–CV pairs from FDA drug labels, representing 15 targeted
drugs and 75 CV events. These pairs are of high quality and
Table 1
Targeted drug usage and prevalence of CV events in cancer vs. non-cancer patients.
Patients Targeted
drugs (%)
CVs_targeted
(%)
Polypharmacy Comorbidity
Cancer patients
N = 443,226
(10.34%)
47.7 39.0 4.62 1.45
Non-cancer patients
N = 3,841,871
(89.66%)
2.56 32.7 3.09 1.25
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2.2.3. Filtering extracted drug–CV pairs
We investigated three ﬁltering schemes to improve the preci-
sion of the extracted drug–CV pairs. Normally, for a patient taking
n drugs and reporting m CV events, a total of n *m drug–CV pairs
are possible. At least three factors can contribute to false positives:
(1) misattribution among drugs and CVs; (2) some of the reported
side effects are in fact indications of some of the drugs a patient is
taking; and (3) the reported side effects are in fact manifestations
of the diseases. We developed three different ﬁltering algorithms
to deal with each of the above-mentioned scenarios. The ﬁltered
drug–CV pairs were then ranked. Ranked performance of the ﬁl-
tered pairs was compared to that of unﬁltered pairs.
2.2.3.1. Filter 1: Extracting drug–CV pairs from patients taking a single
drug. As is later shown, cancer patients in FAERS, on average, took
4.62 drugs at the same time. Therefore, misattribution between
drugs and CV events can be a signiﬁcant problem contributing to
false positives. The ﬁrst ﬁltering approach was to extract drug–
CV pairs from patients who only took one drug, which is a targeted
drug, and also reported at least one CV event.
2.2.3.2. Filter 2: removing known drug–disease treatment pairs from
extracted drug–CV pairs. As our Results section indicates, about 25%
of drug–CV pairs that appeared in both FAERS and in biomedical
literature were in fact drug–disease treatment pairs. Our second
ﬁltering approach was to systematically remove all known drug–
disease treatment pairs from extracted drug–CV pairs. We com-
piled a large dataset consisting of 184,442 drug–disease treatment
pairs by combining information from FAERS (52,066 pairs) and
clinicaltrials.gov (139,669 pairs). Pairs from FAERS were extracted
by linking DRUGyyQq.TXT to INDIyyQq.TXT (with named entity
recognition and mapping for both drugs and diseases). Drug–dis-
ease treatment pairs from clinicaltrials.gov were generated in
one of our recent studies [11]. For each patient, we ﬁltered out
known drug–disease treatment pairs from the drug–CV pairs.
2.2.3.3. Filter 3: removing known disease–CV manifestation associa-
tions from patient records. Cardiovascular diseases often co-occur
in cancer patients since the incidence of both increases with age.
Therefore it is likely that the reported cardiotoxicities are in fact
the clinical manifestations of co-morbid cardiovascular events in
cancer patients. We extracted a total of 50,551 disease–manifesta-
tion pairs from the Uniﬁed Medical Language System (UMLS) (2011
version) ﬁle MRREL.RRF [32]. We then expanded the terms in the
pairs to include all the synonyms in order to capture disease term
usage variations in FAERS. After expansion, we obtained a total of
349,987 pairs, which were then used to ﬁlter out side effects that
are known manifestations (symptoms) of diseases being treated.
For each patient, we simply removed all side effects that are known
clinical manifestations of the patient’s disease. Then, drug–CV pairs
were extracted from the ﬁltered patient records.
2.2.4. Manual conﬁrmation of drug–CV pairs using supporting
evidence from MEDLINE
In one of our previous studies [11], we built a local MEDLINE
search engine with indices on a total of 21,354,075 MEDLINE re-
cords (119,085,682 sentences) published between 1965 and
2012. For each targeted drug–CV pair extracted from FAERS, we re-
trieved all of its associated MEDLINE sentences using the local
search engine. In total, we retrieved 3628 sentences from MED-
LINE. We then manually classiﬁed these pairs into three classes
(CAUSE, TREAT and NONE) using the sentences (and abstracts
when necessary) as evidence. Three curators with graduatedegrees in clinical or biomedical science performed the curation
task. Each curator independently curated all the sentences (a total
of 25 h/each curator). For each drug–CV pairs, if there is one sen-
tence that provides supporting evidence for causal relationship,
then it is determined as positive (even though other sentences
may show contradictory/inconclusive evidence). Majority vote
was used to decide the ﬁnal classiﬁcation of each drug–CV pair.
We found the inter-annotator agreement is as high as 86%.3. Results
3.1. Many cancer patients are under targeted therapy and reported
signiﬁcantly more CV events than non-cancer patients
There are a total of 4,285,097 patient records in FAERS, among
which 443,226 (10.34%) are of cancer patients and 3,841,871
(89.66%) are of non-cancer patients. About half of cancer patients
(47.7%) took at least one targeted drug (Table 1). Only a small per-
centage of non-cancer patients (2.56%) took targeted drugs. About
39.0% cancer patients taking targeted drugs also reported at least
one cardiovascular adverse event, indicating that cardiovascular
safety is indeed a signiﬁcant issue of targeted therapy in cancer pa-
tients. Note that even though these 45 target drugs were used in
treating cancers, they are also used in treating non-cancer diseases.
For example, bevacizumab is FDA-approved drug for the treatment
of colorectal cancer and lung cancer, it is also used in treating eye
diseases such as age-related macular degeneration (AMD) and dia-
betic retinopathy. The prevalence of targeted drug-associated CV
events in cancer patients is signiﬁcantly higher than that in non-
cancer patients (39.0% vs. 32.7%, Z-score is 12.538 and p-value = 0),
indicating that risk factors other than the drug itself, such as drug
combination, disease characteristics, and co-morbidities, may con-
tribute to this increased prevalence. Cancer patients also tended to
use signiﬁcantly more drugs (average of 4.62) than non-cancer pa-
tients (average of 3.09). The average number of co-morbidities in
cancer patients is 1.45, which is also signiﬁcantly higher than
1.25 in non-cancer patients. Since cancer patients are often under
the treatment of multiple drugs and also have co-morbidities,
accurately extracting drug–SE pairs, including drug–CV pairs, is a
challenging task. In the following sections, we present methods
to rank lowly and ﬁlter out false positives.3.2. Ranking by co-occurrence frequency is more effective than
standard signal detection methods
We compared six different ranking measures: frequency (Freq),
relative reporting ratio (RRR), proportional reporting ratio (PRR),
reporting odds ratio (ROR), phi coefﬁcient (PhiCorr), and informa-
tion component (IC). We extracted a total of 11,173 drug–CV pairs,
representing 39 targeted cancer drugs and 1095 CVs. We used the
259 drug–CV pairs from FDA drug labels as gold standard to com-
pare the precisions at 11 recall values. Note that the precisions
measured using this gold standard did not necessarily represent
Fig. 2. Ranked precisions at 11 recalls for three ranking measures: frequency (Freq),
proportional reporting ratio (PRR) and phi coefﬁcient (PhiCorr).
Fig. 3. Ranked precisions at 11 recalls for three different ﬁltering schemes:
‘‘Single_Drug_Patients’’ (pairs from patients taking one drug), ‘‘Minus_Treate-
ment_Pairs’’ (ﬁltered out drug–disease treatment pairs), ‘‘Minus_manifestation’’
(ﬁltered out disease manifestations).
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in FDA drug labels. As shown in Fig. 2, ranking by co-occurrence
signiﬁcantly improved the precisions of top-ranked pairs; the pre-
cision of top-ranked pairs (recall = 0.1) was 0.208, a more than
800% elevation in precision compared to 0.023 at recall of 1.0
(the whole list). In addition, ranking by co-occurrence is more
effective than all ﬁve other methods. At a recall of 0.1, the precision
was 0.208 for frequency-based ranking, which is 246% increase
compared to the 0.06 for ranking by PRR. Ranking by all other ﬁve
methods had no effects on ranking known drug–CV pairs highly
(data for RRR, ROR and IC were similar to that for PRR and is not
shown). The ineffectiveness of the widely adopted signal detection
methods such as PRR in ranking targeted drugs-related CVs may be
partly due to inherent data biases. In fact, many known drug–CV
pairs from FDA drug labels had low, even negative, PRR values.
Even though the top pairs ranked by frequency were signiﬁ-
cantly enriched with true positives compared to the whole list,
the precision was still very low (0.208 at a recall of 0.1 and 0.180
at a recall of 0.2). There are at least two explanations for these
low precisions. First, not all signals from FAERS were included in
FDA drug labels, resulting in false negatives. The information from
FDA drug labels was mainly sourced from controlled clinical trials,
which do not necessarily reﬂect the ‘real-world’ clinical practice.
The information from FAERS reﬂects the actual clinical situation,
where the presence of co-morbidities, age, and other risk factors
may contribute to cardiovascular events in cancer patients. As
shown later in this study, 80.9% true positive drug–CV pairs that
appeared in both FAERS and published literature were not cap-
tured by the FDA drug labels, clearly demonstrating that using
drug–CV pairs included in FDA drug labels as gold standard will
greatly under-estimate the actual precision of drug–CV pairs ex-
tracted from FAERS. The second cause of the low precision of
top-ranked pairs may be true negatives, since not all top-ranked
pairs are necessarily true signals. Even if a drug and a CV event ap-
pear together many times, it is still possible that the underlying
diseases or other drugs in a combination therapy may contribute
to the CV event. On the other hand, even though a cardiovascular
event appeared with a targeted drug only once in the database, it
is still likely to be a true association, which may only appear in
some speciﬁc patients with certain demographic and disease char-
acteristics. Another caveat in using well-known drug–SE pairs from
FDA drug labels as gold standard is that it will particularly under-
estimate the precision of low-incidence or idiosyncratic events in
cancer patients. In fact, to identify, understand, and predict these
rare events in cancer patients is perhaps the most important and
challenging task.3.3. Drug–CV pairs extracted from patients taking only one drug have
the most improved precision of all pairs
At least three possible factors may contribute to the low preci-
sion of extracted drug–CV pairs: (1) inclusion of CV events caused
by drugs other than the targeted cancer drugs; (2) inclusion of
drug–disease treatment pairs; and (3) the possibility that reported
adverse events are clinical manifestations of a patient’s existing
diseases.
We extracted a total of 4549 drug–CV pairs from patients who
took only one drug and reported at least one CV event, and ranked
the pairs by frequency. As shown in Fig. 3, these pairs had higher
precisions than unﬁltered pairs at 9 recalls. The overall precision
of drug–CV pairs extracted from patients taking single drug is
0.044, which represents a 91.3% increase from the precision of
0.023 for unﬁltered pairs.
However, the other two ﬁltering approaches, ﬁltering out
known drug–disease treatment pairs from extracted drug–CV pairs
and removing known clinical manifestations from reported side ef-
fects, had no effect on precisions (Fig. 3). As our results show, about
25% of drug–CV pairs that appeared in both FAERS and biomedical
literature were in fact drug–disease treatment pairs. The ineffec-
tiveness in improving precision by ﬁltering out known drug–dis-
ease treatment pairs may be due to the limited coverage of our
compiled drug–disease treatment pairs, even though it consisted
of 184,442 pairs. The same explanation can apply to the ﬁltering
approach by removing known disease manifestations.
The higher precision of pairs extracted from patients taking a
single drug when evaluated with pairs from FDA drug labels re-
ﬂects the fact that these patients may be more similar to patients
in controlled clinical trials (less co-comorbities, taking less multi-
ple drugs simultaneously). Some CV events may manifest only
when targeted drugs are used in combination with each other or
with other cancer therapies such as chemotherapy or radiotherapy.3.4. Systematically curation of drug–CV pairs that appeared in
MEDLINE sentences
We used evidence from the vast amount of published literature
to systematically conﬁrm extracted drug–CV pairs. Among 11,173
drug–CV pairs extracted from FAERS, only 617 pairs also appeared
in MEDLINE sentences. We retrieved a total of 3628 sentences that
these 617 pairs appeared in and manually curated these sentences.
Among the 617 pairs that also appeared in MEDLINE sentences,
320 pairs (51.9%) were true positive (CAUSE) pairs, demonstrating
that if a pair appears in both FAERS and in the literature, it is highly
Table 2
Manual curation of all drug–CV pairs that appeared in both FAERS and MEDLINE
sentences.
Pairs CAUSE TREAT NONE CAUSE pairs not
included in FDA drug labels
617 320 154 143 258
51.9% 25.0% 23.1% 80.6%
The true positive rate and the percentage of pairs that are not included in FDA drug
labels are highlighted.
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fact drug–disease treatment pairs, demonstrating that the inclu-
sion of drug–disease treatment pairs can adversely affect precision.
The reason that our strategy of ﬁltering out known drug–disease
treatment pairs was not effective in improving precision might
be due to the limited coverage of the drug–disease treatment data-
set. The rest of the 143 pairs (23.1%) have no obvious semantic
relationships based on the evidence sentences (Table 2).
More signiﬁcantly, among the 320 true positive pairs, 258 pairs
(80.6%) are not included in the FDA drug labels even though there
exists evidence from both FAERS and published literature. These
pairs along with their associated MEDLINE sentences and FAERS
counts are available at: http://nlp.case.edu/public/data/Targeted-
CancerDrug_Cardiotoxicity_AERS/3_manual_curation.
In summary, even though the presence of FAERS reported drug–
CV pairs in MEDLINE sentences is low, among the 617 pairs that
did appear in MEDLINE sentences, 51.9% are true positives. 80.6%
of these true positives are not included in current FDA drug labels,
demonstrating the importance of active monitoring of post-mar-
keting cardiovascular events reportedly associated with targeted
drugs in cancer patients. As we mentioned before, the knowledge
in FAERS and in published literature is largely complementary. In
this study, we only checked 618 drug–CV pairs that appeared in
both FAERS and in the literature. However, we do not know how
many drug–CV pairs appeared in literature, but not in FAERS or
FDA drug labels.4. Discussion
In this study, we systematically mined and manually conﬁrmed
post-marketing cardiovascular events associated with targeted
anticancer drugs. To the best of our knowledge, this is the ﬁrst at-
tempt at creating a knowledge base of drug–CV associations for tar-
geted cancer drugs. However, several limitations must be
considered. First, the true precision of the extracted drug–CV pairs
is unknown. Evaluations using drug–CV pairs extracted from FDA
drug labels may have signiﬁcantly underestimated the true preci-
sion. The cardiovascular adverse events for targeted cancer drugs
from FDA drug labels were mainly from clinical trials and the ones
in FAERS are from ‘real-world’ patients (older patients or patients
with signiﬁcant co-morbidities). Manual evaluation with evidence
from MEDLINE also has its own limitations and biases since we
can only calculate the precision of the pairs that appeared in both
FAERS and MEDLINE. Second, targeted cancer therapies are often
used in combination with other cancer treatments, including other
targeted therapies, chemotherapy, and radiotherapy. The risk of
certain cardiovascular events may increase when the targeted
drugs are used in combination. At present, the drug–CV pairs we ex-
tracted from FAERS are only for single drugs. It will be interesting to
investigate whether combinations of targeted cancer drugs may
lead to speciﬁc cardiotoxicities due to synergistic actions. Finally,
it will be important to identify potential risk factors for drug-in-
duced cardiovascular events. These risk factors may include patient
demographics such as age and gender, patient characteristics suchas smoking status and physical stress, disease characteristics such
as cancer types and co-morbidities, and prior cancer treatments.
All these factors can potentially affect the presence and severity
of cardiovascular events associated with targeted drug therapy in
cancer patients. Ideally, results from this study will guide similar
future studies of toxic effects of cancer treatments.
In this study, we mined targeted drug-associated cardiovascular
events from FAERS. To make the knowledge base more complete,
other data sources are necessary, including the vast amount of
published biomedical literature [11], the patient electronic medical
records [32] and even the Web [33,34]. For example, a recent study
shows that mining consumers’ web search history can reveal unre-
ported side effects of drugs or drug combinations [33]. Our study in
building a targeted cancer drug-associated cardiotoxicity knowl-
edge base from FAERS is the ﬁrst step towards mechanistic under-
standing of these adverse events. In-depth meta-analysis or
network-based systems approach can be performed by combining
this knowledge base with other data, such as patients’ age, gender,
disease characteristics, drug–drug combinations, drug targets, and
drug metabolism.5. Conclusions
In this study, we present automatic approaches in mining car-
diovascular events associated with targeted cancer drugs from
FDA post-marketing FAERS database. We have built a database
consisted of 11,173 post-marketing cardiovascular events associ-
ated with targeted cancer drugs. We have developed signal extrac-
tion, ranking, ﬁltering, and conﬁrming approaches to improve the
precision of the dataset. The unique drug–CV relationship dataset
we created could capacitate the development of computational
models that would in turn facilitate our understanding and predic-
tion of cardiotoxic effects associated with targeted drugs, and help
us to achieve more effective, safer, and more personalized cancer
care.Data availability
http://nlp.case.edu/public/data/TargetedCancerDrug_Cardiotoxicity_
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